ATE381620T1 - Synthetische bidirektionale promotoren und deren verwendungen - Google Patents
Synthetische bidirektionale promotoren und deren verwendungenInfo
- Publication number
- ATE381620T1 ATE381620T1 AT04728627T AT04728627T ATE381620T1 AT E381620 T1 ATE381620 T1 AT E381620T1 AT 04728627 T AT04728627 T AT 04728627T AT 04728627 T AT04728627 T AT 04728627T AT E381620 T1 ATE381620 T1 AT E381620T1
- Authority
- AT
- Austria
- Prior art keywords
- promotors
- expression
- bidirectional
- synthetic bidirectional
- synthetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
- C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46508003P | 2003-04-24 | 2003-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE381620T1 true ATE381620T1 (de) | 2008-01-15 |
Family
ID=33310991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04728627T ATE381620T1 (de) | 2003-04-24 | 2004-04-21 | Synthetische bidirektionale promotoren und deren verwendungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8501464B2 (de) |
| EP (1) | EP1616012B1 (de) |
| JP (1) | JP2006524051A (de) |
| AT (1) | ATE381620T1 (de) |
| AU (1) | AU2004233315A1 (de) |
| CA (1) | CA2523138C (de) |
| DE (1) | DE602004010799T2 (de) |
| DK (1) | DK1616012T3 (de) |
| ES (1) | ES2298745T3 (de) |
| WO (1) | WO2004094642A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| EP2188386A2 (de) * | 2007-09-17 | 2010-05-26 | Universite De Strasbourg | Verfahren für den nachweis oder die quantifizierung einer verkürzten mutation |
| WO2010075956A1 (de) | 2008-12-16 | 2010-07-08 | C-Lecta Gmbh | Expressionsvektor |
| WO2010127166A2 (en) * | 2009-04-30 | 2010-11-04 | The Regents Of The University Of California | Combination anti-hiv vectors, targeting vectors, and methods of use |
| US9719146B2 (en) | 2009-09-09 | 2017-08-01 | General Electric Company | Composition and method for imaging stem cells |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CN101851637B (zh) * | 2010-01-15 | 2011-12-14 | 中国农业科学院北京畜牧兽医研究所 | 一种制备同时表达多个基因的转基因动物的方法 |
| WO2012004778A1 (en) * | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| WO2013078433A1 (en) | 2011-11-23 | 2013-05-30 | University Of Hawaii | Auto-processing domains for polypeptide expression |
| WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| JP6735288B2 (ja) * | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス |
| WO2017096363A1 (en) * | 2015-12-04 | 2017-06-08 | Board Of Regents, The University Of Texas System | Reporter system for detecting and targeting activated cells |
| CA3012695A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| HUE055862T2 (hu) * | 2016-04-20 | 2021-12-28 | Centro De Investig Energeticas | Készítmények és eljárások PKLR fokozott génexpressziójára |
| KR101864581B1 (ko) * | 2016-11-04 | 2018-07-13 | 국립암센터 | 양방향 프로모터를 포함하는 렌티바이러스 발현 벡터 및 이의 용도 |
| WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| EP3346001A1 (de) | 2017-01-06 | 2018-07-11 | TXCell | Monospezifische regulatorische t-zellpopulation mit zytotoxizität gegenüber b-zellen |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| SG11202002520UA (en) | 2017-09-19 | 2020-04-29 | Univ British Columbia | Anti-hla-a2 antibodies and methods of using the same |
| EP3684822A4 (de) | 2017-09-20 | 2021-06-16 | The University of British Columbia | Neue anti-hla-a2-antikörper und verwendungen davon |
| SG11202002263TA (en) | 2017-10-16 | 2020-04-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
| AU2019250692A1 (en) | 2018-04-13 | 2020-11-05 | Sangamo Therapeutics France | Chimeric antigen receptor specific for Interleukin-23 receptor |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| EP3833766A1 (de) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nukleinsäuremoleküle und verwendungen davon zur nichtviralen gentherapie |
| KR20210046006A (ko) | 2018-08-10 | 2021-04-27 | 상가모 테라퓨틱스 프랑스 | Tnfr2 도메인을 포함하는 신규한 car 작제물 |
| WO2020081759A1 (en) * | 2018-10-17 | 2020-04-23 | Texas Tech University System | Multivalent virus like particle vaccines |
| GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| WO2020104467A1 (en) * | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant vectors suitable for the treatment of ipex syndrome |
| JP7644007B2 (ja) | 2018-12-06 | 2025-03-11 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| KR20220097891A (ko) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | 렌티바이러스 벡터 제형 |
| EP3808766A1 (de) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor |
| EP4103591A4 (de) | 2020-02-13 | 2024-09-04 | The Board of Trustees of the Leland Stanford Junior University | T-zellen und hämatopoetische stammzellenvorläufer zur behandlung von patienten mit ipex-syndrom basierend auf dem foxp3-gen (crispr) |
| WO2021186056A1 (en) | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
| WO2022046665A1 (en) | 2020-08-23 | 2022-03-03 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| CN113106091B (zh) * | 2021-03-04 | 2022-08-16 | 杭州师范大学 | 一种植物叶片高表达双向启动子及其应用 |
| MX2024002333A (es) | 2021-08-23 | 2024-03-07 | Bioverativ Therapeutics Inc | Sistema de expresion de baculovirus. |
| AU2022332276A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| EP4396216A1 (de) | 2021-09-03 | 2024-07-10 | Sangamo Therapeutics, Inc. | Mog-bindende proteine und verwendungen davon |
| WO2023056194A2 (en) * | 2021-09-29 | 2023-04-06 | Chimera Bioengineering, Inc. | Compositions and methods for anti-tnmuc1 gold car t-cells |
| TW202346327A (zh) | 2021-09-30 | 2023-12-01 | 美商百歐維拉提夫治療公司 | 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸 |
| CN119137278A (zh) * | 2022-03-24 | 2024-12-13 | 细胞和大脑有限公司 | 新型重组载体及其用途 |
| US20250197888A1 (en) * | 2022-03-24 | 2025-06-19 | Cell & Brain Co., Ltd. | Novel recombinant vector and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6136597A (en) * | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| AU751259B2 (en) | 1997-12-12 | 2002-08-08 | Onyx Pharmaceuticals, Inc. | Selective killing and diagnosis of p53+ neoplastic cells |
| AU749059B2 (en) | 1997-12-12 | 2002-06-20 | Cell Genesys, Inc. | Therapeutic use of lentiviral vectors |
| JP4482639B2 (ja) | 1998-11-13 | 2010-06-16 | ジービーピー アイピー， エルエルシー | レンチウイルスベクターに対する効率的なパッケージング細胞を産生するための選択システム |
| EP1129178A4 (de) | 1998-11-13 | 2002-08-21 | Cell Genesys Inc | Empfindliches 'screening'-system für rekombinante viren mit defekter hülle. |
| EP1173615A2 (de) | 1999-04-30 | 2002-01-23 | Advance Sentry Corporation | System und verfahren zum screening auf karzinome der nasalen pharynx |
| US6630324B1 (en) * | 1999-07-29 | 2003-10-07 | Baylor College Of Medicine | Aldehyde reductase bidirectional promoter and its use |
| US6780639B1 (en) * | 1999-08-24 | 2004-08-24 | Universite Libre De Bruxelles | Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization |
| WO2001089580A1 (en) | 2000-05-22 | 2001-11-29 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Systemic and cardiovascular transduction with lentiviral vectors |
| JP2003033179A (ja) * | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | 可逆的遺伝子導入ベクター |
| US20050233457A1 (en) * | 2002-04-15 | 2005-10-20 | Andreas Block | Recombining viral vectors for the tetracycline-regulated expression of genes |
-
2004
- 2004-04-21 ES ES04728627T patent/ES2298745T3/es not_active Expired - Lifetime
- 2004-04-21 CA CA2523138A patent/CA2523138C/en not_active Expired - Lifetime
- 2004-04-21 AT AT04728627T patent/ATE381620T1/de not_active IP Right Cessation
- 2004-04-21 WO PCT/IT2004/000227 patent/WO2004094642A2/en not_active Ceased
- 2004-04-21 JP JP2006507649A patent/JP2006524051A/ja active Pending
- 2004-04-21 DK DK04728627T patent/DK1616012T3/da active
- 2004-04-21 US US10/554,181 patent/US8501464B2/en active Active
- 2004-04-21 AU AU2004233315A patent/AU2004233315A1/en not_active Abandoned
- 2004-04-21 EP EP04728627A patent/EP1616012B1/de not_active Expired - Lifetime
- 2004-04-21 DE DE602004010799T patent/DE602004010799T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004094642A2 (en) | 2004-11-04 |
| US8501464B2 (en) | 2013-08-06 |
| DE602004010799T2 (de) | 2009-01-22 |
| DE602004010799D1 (de) | 2008-01-31 |
| JP2006524051A (ja) | 2006-10-26 |
| CA2523138C (en) | 2013-04-23 |
| EP1616012B1 (de) | 2007-12-19 |
| ES2298745T3 (es) | 2008-05-16 |
| DK1616012T3 (da) | 2008-04-21 |
| CA2523138A1 (en) | 2004-11-04 |
| US20060200869A1 (en) | 2006-09-07 |
| EP1616012A2 (de) | 2006-01-18 |
| WO2004094642A3 (en) | 2005-05-12 |
| AU2004233315A1 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE381620T1 (de) | Synthetische bidirektionale promotoren und deren verwendungen | |
| ATE287046T1 (de) | Betätigungseinrichtung | |
| BRPI0417825A (pt) | métodos para uso de lactobacilli probióticos para animais de estimação | |
| DK2284266T3 (da) | sIRNA-MOLEKYLE MOD TP53 | |
| BRPI0417823A (pt) | métodos para uso de bifidobactérias probióticas para animais de estimação | |
| CY1117027T1 (el) | Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων | |
| EP3018140A3 (de) | Inaktivierung von glutamylpolypeptidsynthese in bacillus | |
| CY1110557T1 (el) | Αντισωματα ιντερλευκινης-10 | |
| MXPA02012743A (es) | Moleculas tipo il-17 y usos de las mismas. | |
| DE60138715D1 (de) | Tnf-rezeptor-ähnliche moleküle und deren anwendungen | |
| IT1319258B1 (it) | Catalizzatore per la idrodeclorurazione del tetracloruro di carbonio acloroformio. | |
| DE60031395D1 (de) | Mikrobielle beta-glukuronidase gene, genprodukte und deren verwendungen | |
| SG154318A1 (en) | Cross-tie | |
| BRPI0409276A (pt) | derivados de piperazina inibidores de renina | |
| ATE505549T1 (de) | Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung | |
| ATE419265T1 (de) | Benzoat- und antranilatinduzierbare promotoren | |
| EP1563214A4 (de) | Schlauch mit modifiziertem 6/12 nylonmaterial | |
| NZ334839A (en) | Polynucleotide molecules encoding neospora proteins and uses thereof | |
| DE69533626D1 (de) | Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung | |
| DK1664102T3 (da) | Isoleret photoprotein mtclytin, samt dets anvendelse | |
| MXPA05005120A (es) | Secuencias de adn de la region genomica tcd de photorhabdus luminescens. | |
| ID27620A (id) | Medium kultur untuk pembiakan lactobacillus clearans, dan metode pengawetan galur termaksud | |
| AR020759A1 (es) | Proceso de oxidacion selectiva y catalizador para el mismo | |
| DE69631899D1 (de) | Xylanasen, für diese kodierende gene und anwendungen derselben | |
| ATE334215T1 (de) | Verwendung des aminoglycosidresistenzgens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1616012 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |